Company news

Beam Therapeutics Inc. news in 2025

Beam Therapeutics Inc.'s news releases, calls and decks from 2025, newest first.

View company

Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

December 17, 2025

Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

December 5, 2025

Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference

November 11, 2025

Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

November 3, 2025

Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

November 2, 2025

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

August 24, 2025

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

August 13, 2025

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

August 5, 2025

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

June 12, 2025

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

June 2, 2025

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 28, 2025

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

May 13, 2025

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

May 12, 2025

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 11, 2025

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 5, 2025

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

April 4, 2025

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

March 26, 2025

Beam Therapeutics Announces Pricing of Underwritten Offering

March 9, 2025

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

March 9, 2025

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

February 24, 2025

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

February 23, 2025

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

January 29, 2025

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

January 22, 2025

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

January 12, 2025

Decks in 2025